The global obstetrics and gynecology drugs market was valued at USD 14.07 billion in 2022 and is anticipated to grow at a CAGR of 7.6% from 2022 to 2030. The global obstetrics and gynecology drugs market is expected to reach USD 25.28 billion by 2030. Europe is expected to grow the fastest during the forecast period. 

Gynecology and Obstetrics encompass diverse medical conditions relating to women's reproductive systems. Women's lifestyle changes have led to increased obstetric and gynecological disorders affecting the appendages, the uterus, and the ovaries. Several symptoms associated with gynecologic problems affect a female's reproductive system, including vaginal tingling and vaginal release.

The COVID-19 outbreak has prompted the pharmaceutical industry into action, which has impacted the management of patients with obstetrics and gynecology diseases due to a race for therapeutic and preventive drugs. In addition to treating cancers of the reproductive system, obstetrics and gynecology drugs are also used to treat menstrual disorders, such as menorrhagia, cramping and pre-menstrual syndrome.

Revenue growth of the obstetrics and gynecology drugs market is driven by rising awareness regarding diagnosing and treating menstrual disorders and pregnancy-related infections. In recent years, acupuncture, Su Jok therapy, homoeopathy, and yoga have gained popularity and are slowly replacing some traditional hospital practices.

Moreover, genetic sequencing and precision medicine are being combined by pharmaceutical companies to develop new cancer treatments and drug therapies. Additionally, a growing geriatric female population and revitalized economic growth are likely to contribute to the growth of obstetrics and gynecology drugs. Continuous research and development are going on in the pharmaceutical industry to develop more efficient and innovative drugs with more healing effects and that can cover a wide spectrum of obstetrics and gynecology diseases.